Omeros (NASDAQ:OMER) Sees Large Volume Increase – Still a Buy?

Omeros Corporation (NASDAQ:OMER) saw unusually-high trading volume on Friday . Approximately 1,781,410 shares traded hands during trading, an increase of 3% from the previous session’s volume of 1,724,296 shares.The stock last traded at $14.4530 and had previously closed at $15.36.

Analyst Ratings Changes

OMER has been the subject of several recent research reports. WBB Securities reissued a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a report on Wednesday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. D. Boral Capital restated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Omeros has a consensus rating of “Moderate Buy” and a consensus target price of $33.67.

Omeros Stock Down 5.1%

The firm has a market capitalization of $1.03 billion, a PE ratio of -7.21 and a beta of 2.48. The stock has a 50-day moving average price of $8.91 and a 200 day moving average price of $5.73.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.39. As a group, equities analysts predict that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omeros

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its position in shares of Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 5,677 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Omeros during the first quarter worth $88,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Omeros in the second quarter valued at about $32,000. Tower Research Capital LLC TRC lifted its stake in shares of Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 11,971 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in Omeros during the second quarter worth about $40,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.